Renin–angiotensin system and neprilysin

João Pedro Ferreira and Patrick Rossignol

in The ESC Textbook of Cardiovascular Medicine

Third edition

Published on behalf of European Society of Cardiology

Published in print December 2018 | ISBN: 9780198784906
Published online July 2018 | e-ISBN: 9780191827143 | DOI:

Series: The European Society of Cardiology Series

Renin–angiotensin system and neprilysin

More Like This

Show all results sharing this subject:

  • Cardiovascular Medicine


Show Summary Details


The advent of drugs able to modulate the renin–angiotensin system (RAS), and more recently the neprilysin inhibitor sacubitril in combination with a RAS blocker, has improved the outcome of many cardiovascular and renal conditions. In particular, heart failure, post-myocardial infarction, and hypertension are the cardiovascular clinical syndromes in which RAS inhibition (and in heart failure, in combination with neprilysin inhibition) has greatly improved morbidity and mortality. This chapter aims to provide an appraisal of RAS and neprilysin inhibitors regarding their pharmacological properties with respect to mechanism(s) of action, pharmacokinetics, monitoring, adverse effects, and drug interactions.

Chapter.  5697 words.  Illustrated.

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.